Overview
Background
Associate Professor Paul Griffin is the Director of Infectious Diseases at Mater Health Services in Brisbane and Associate Professor of Medicine at the University of Queensland Medical School. He has fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine.
Paul is the Principal Investigator and Medical Director at Nucleus Network, a specialized contract research organisation specializing in early and late phase trials in infectious diseases where he has been the principal investigator on in excess of 125 clinical trials, predominantly in Infectious Diseases including novel vaccines and Malaria human challenge studies. This includes 8 vaccines for COVID-19 and a number of COVID-19 therapies.
As a Clinical Microbiologist, he maintains an active interest in diagnostic microbiology with a focus on clinical applications of faecal microbiome metagenomic sequencing.
In addition to a teaching role at the University of Queensland, Paul is also the chair of the Advanced Training Committee in Infectious Diseases with the Royal Australasian College of Physicians, the committee that oversees the training of Infectious Diseases specialists in Australia.
Finally, as a director and scientific advisory board member of the immunisation coalition, Paul has an active interest in vaccine education and advocacy and has become a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.
Availability
- Professor Paul Griffin is:
- Available for supervision
- Media expert
Fields of research
Research impacts
While performing vital clinical and research duties, he has also devoted time to inform, educate and reassure the community via a wide range of media appearances. He has featured regularly on prominent Australian programs across television, radio, print and online including The Project, Sunrise, Today Show, A Current Affair, and internationally including Canada’s CTV and the BBC.
Works
Search Professor Paul Griffin’s works on UQ eSpace
2024
Journal Article
QuantumEyes: Towards Better Interpretability of Quantum Circuits
Ruan, Shaolun, Guan, Qiang, Griffin, Paul, Mao, Ying and Wang, Yong (2024). QuantumEyes: Towards Better Interpretability of Quantum Circuits. IEEE Transactions on Visualization and Computer Graphics, 30 (9), 6321-6333. doi: 10.1109/tvcg.2023.3332999
2024
Journal Article
Revolutionising RSV infection prevention and control Unveiling new options in the fight against RSV
Spence, Luke, Armstrong, Mark R. and Griffin, Paul M. (2024). Revolutionising RSV infection prevention and control Unveiling new options in the fight against RSV. Medicine Today, 25 (7), 45-54.
2024
Journal Article
<i>VIOLET</i>: <u>V</u>isual Analyt<u>i</u>cs f<u>o</u>r Exp<u>l</u>ainable Quantum N<u>e</u>ural Ne<u>t</u>works
Ruan, Shaolun, Liang, Zhiding, Guan, Qiang, Griffin, Paul, Wen, Xiaolin, Lin, Yanna and Wang, Yong (2024). VIOLET: Visual Analytics for Explainable Quantum Neural Networks. IEEE Transactions on Visualization and Computer Graphics, 30 (6), 2862-2874. doi: 10.1109/tvcg.2024.3388557
2024
Journal Article
Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target
Sasso, Etianne Martini, Muraki, Katsuhiko, Eaton-Fitch, Natalie, Smith, Peter, Jeremijenko, Andrew, Griffin, Paul and Marshall-Gradisnik, Sonya (2024). Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target. Frontiers in Immunology, 15. doi: 10.3389/fimmu.2024.1264702
2024
Journal Article
Seasonal vaccination Bracing for winter
Armstrong, Mark R., Spence, Luke and Griffin, Paul M. (2024). Seasonal vaccination Bracing for winter. Medicine Today, 25 (5), 12-18.
2024
Journal Article
Bracing for impact Navigating the complexities of the 2024 influenza season in Australia
Spence, Luke, Armstrong, Mark R. and Griffin, Paul M. (2024). Bracing for impact Navigating the complexities of the 2024 influenza season in Australia. Medicine Today, 25 (5), 39-48.
2024
Journal Article
A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness
Plotnik, David, Sager, Jennifer E., Aryal, Madhukar, Fanget, Marie C., Peter, Alessia, Schmid, Michael A., Cebrik, Deborah, Mogalian, Erik, Boundy, Keith, Yeh, Wendy W., Griffin, Paul and Reyes, Maribel (2024). A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness. Antimicrobial Agents and Chemotherapy, 68 (4). doi: 10.1128/aac.01273-23
2024
Journal Article
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
Bennett, Chijioke, Woo, Wayne, Bloch, Mark, Cheung, King, Griffin, Paul, Mohan, Rahul, Deshmukh, Sachin, Arya, Mark, Cumming, Oscar, Neville, A Munro, McCallum Pardey, Toni G, Plested, Joyce S, Cloney-Clark, Shane, Zhu, Mingzhu, Kalkeri, Raj, Patel, Nita, Marcheschi, Alex, Swan, Jennifer, Smith, Gale, Cho, Iksung, Glenn, Gregory M, Walker, Robert, Mallory, Raburn M, Anderson, Anna, Ang, Mary, Barnes, Timothy, Bassin, Michelle, Bessey, Kate, Bowler, Simon ... Young, Rhys (2024). Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial. The Lancet Infectious Diseases, 24 (6), 581-593. doi: 10.1016/S1473-3099(24)00077-X
2023
Journal Article
Immunogenicity and safety of heterologous omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3 randomized clinical trial
Bennett, Chijioke, Rivers, E. Joy, Woo, Wayne, Bloch, Mark, Cheung, King, Griffin, Paul, Mohan, Rahul, Deshmukh, Sachin, Arya, Mark, Cumming, Oscar, Neville, A. Munro, Pardey, Toni McCallum, Plested, Joyce S., Cloney-Clark, Shane, Zhu, Mingzhu, Kalkeri, Raj, Patel, Nita, Buchanan, Agi, Marcheschi, Alex, Swan, Jennifer, Smith, Gale, Cho, Iksung, Glenn, Gregory M., Walker, Robert and Mallory, Raburn M. (2023). Immunogenicity and safety of heterologous omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3 randomized clinical trial. Journal of Infectious Diseases, 230 (1), e4-e16. doi: 10.1093/infdis/jiad508
2023
Journal Article
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
Chappell, Keith J., Mordant, Francesca L., Amarilla, Alberto A., Modhiran, Naphak, Liang, Benjamin, Li, Zheyi, Wijesundara, Danushka K., Lackenby, Julia A., Griffin, Paul, Bennet, Jillian K., Hensen, Luca, Zhang, Wuji, Nguyen, Thi H.O., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Kedzierska, Katherine, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R. and Munro, Trent P. (2023). Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial. eBioMedicine, 97 104842. doi: 10.1016/j.ebiom.2023.104842
2023
Journal Article
Strong CD4+T-cell responses to ancestral and variant spike proteins are established by NVX-CoV2373 severe acute respiratory syndrome Coronavirus 2 primary vaccination
Fries, Louis, Formica, Neil, Mallory, Raburn M, Zhou, Haixia, Plested, Joyce S, Kalkeri, Raj, Moldovan, Ioana, Patel, Nita, Albert, Gary, Robinson, Michelle, Cho, Iksung, Chau, Gordon, Dubovsky, Filip, Glenn, Gregory M, Adams, Mark, Arya, Mark, Athan, Eugene, Berger, Ira, Bradley, Paul, Glover, Richard, Griffin, Paul, Kim, Joshua, Kitchener, Scott, Klein, Terry, Leah, Amber, Lemech, Charlotte, Lickliter, Jason, Manning, Mary Beth, Napier-Flood, Fiona ... Turner, Mark (2023). Strong CD4+T-cell responses to ancestral and variant spike proteins are established by NVX-CoV2373 severe acute respiratory syndrome Coronavirus 2 primary vaccination. Journal of Infectious Diseases, 228 (6), 734-741. doi: 10.1093/infdis/jiad163
2023
Journal Article
Barriers to optimal management of syphilis in pregnancy and congenital syphilis in south-east Queensland: a qualitative investigation
Fowler, James A., Warzywoda, Sarah, Nourse, Clare, Wu, Mandy, Britton, Sumudu, Rowling, Diane, Griffin, Paul, Lazarou, Mattea, Hamilton, Zoe and Dean, Judith A. (2023). Barriers to optimal management of syphilis in pregnancy and congenital syphilis in south-east Queensland: a qualitative investigation. Sexual Health, 20 (6), 506-513. doi: 10.1071/sh23119
2023
Journal Article
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study
de Bruyn, Guy, Wang, Joyce, Purvis, Annie, Ruiz, Martin Sanchez, Adhikarla, Haritha, Alvi, Saad, Bonaparte, Matthew I., Brune, Daniel, Bueso, Agustin, Canter, Richard M., Ceregido, Maria Angeles, Deshmukh, Sachin, Diemert, David, Finn, Adam, Forrat, Remi, Fu, Bo, Gallais, Julie, Griffin, Paul, Grillet, Marie-Helene, Haney, Owen, Henderson, Jeffrey A., Koutsoukos, Marguerite, Launay, Odile, Torres, Federico Martinon, Masotti, Roger, Michael, Nelson L., Park, Juliana, Rivera-Medina, Doris Maribel, Romanyak, Natalya ... Davis, Yvonne (2023). Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study. eClinicalMedicine, 62 102109, 102109. doi: 10.1016/j.eclinm.2023.102109
2023
Journal Article
Syphilis in pregnancy: a qualitative investigation of healthcare provider perspectives on barriers to syphilis screening during pregnancy in south-east Queensland
Warzywoda, Sarah, Fowler, James A., Nourse, Clare, Wu, Mandy, Britton, Sumudu, Rowling, Diane, Griffin, Paul, Lazarou, Mattea, Hamilton, Zoe and Dean, Judith A. (2023). Syphilis in pregnancy: a qualitative investigation of healthcare provider perspectives on barriers to syphilis screening during pregnancy in south-east Queensland. Sexual Health, 20 (4), 330-338. doi: 10.1071/sh22193
2023
Journal Article
Expanding the geographic boundaries of Melioidosis in Queensland, Australia
Gassiep, Ian, Grey, Victoria, Thean, Li Jun, Farquhar, Drew, Clark, Julia E., Ariotti, Lawrence, Graham, Rikki, Jennison, Amy V., Bergh, Haakon, Anuradha, Satyamurthy, Dyer, Wendy, James, Christian, Huang, Andrea, Putt, Elise, Pakeerathan, Veenaa, Griffin, Paul M. and Harris, Patrick N. A. (2023). Expanding the geographic boundaries of Melioidosis in Queensland, Australia. The American Journal of Tropical Medicine and Hygiene, 108 (6), 1215-1219. doi: 10.4269/ajtmh.23-0002
2023
Journal Article
Improving care for patients with Clostridioides difficile infection: A clinical practice and healthcare systems perspective
Hocking, Lucy, Wilcox, Mark, Petrosillo, Nicola, Griffin, Paul, Steiner, Theodore, Attara, Gail, Doré, Joel, Cabling, Mark, Stockwell, Stephanie, Romanelli, Robert J. and Marjanovic, Sonja (2023). Improving care for patients with Clostridioides difficile infection: A clinical practice and healthcare systems perspective. Frontiers in Medicine, 9 1033417, 1-21. doi: 10.3389/fmed.2022.1033417
2022
Journal Article
Longitudinal transitions in tobacco use in youth and young adults: A latent transition analysis of the population assessment of tobacco and health study from Wave 1 to 5
Huang, Siyi, Chen, Qiushi, Griffin, Paul, Liu, Guodong and Azagba, Sunday (2022). Longitudinal transitions in tobacco use in youth and young adults: A latent transition analysis of the population assessment of tobacco and health study from Wave 1 to 5. Addictive Behaviors, 138 ARTN 107548. doi: 10.1016/j.addbeh.2022.107548
2022
Journal Article
A multinational Delphi consensus to end the COVID-19 public health threat
Lazarus, Jeffrey V., Romero, Diana, Kopka, Christopher J., Karim, Salim Abdool, Abu-Raddad, Laith J., Almeida, Gisele, Baptista-Leite, Ricardo, Barocas, Joshua A., Barreto, Mauricio L., Bar-Yam, Yaneer, Bassat, Quique, Batista, Carolina, Bazilian, Morgan, Chiou, Shu-Ti, del Rio, Carlos, Dore, Gregory J., Gao, George F., Gostin, Lawrence O., Hellard, Margaret, Jimenez, Jose L., Kang, Gagandeep, Lee, Nancy, Matičič, Mojca, McKee, Martin, Nsanzimana, Sabin, Oliu-Barton, Miquel, Pradelski, Bary, Pyzik, Oksana, Rabin, Kenneth ... Øvrehus, Anne (2022). A multinational Delphi consensus to end the COVID-19 public health threat. Nature, 611 (7935), 332-345. doi: 10.1038/s41586-022-05398-2
2022
Journal Article
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
Mallory, Raburn M., Formica, Neil, Pfeiffer, Susan, Wilkinson, Bethanie, Marcheschi, Alex, Albert, Gary, McFall, Heather, Robinson, Michelle, Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Bin, Chau, Gordon, Robertson, Andreana, Maciejewski, Sonia, Hammond, Holly L., Baracco, Lauren, Logue, James, Frieman, Matthew B., Smith, Gale, Patel, Nita, Glenn, Gregory M., Adams, Mark, Arya, Mark, Athan, Eugene, Berger, Ira, Bradley, Paul, Briskin, Toby, Glover II, Richard ... Turner, Mark (2022). Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases, 22 (11), 1565-1576. doi: 10.1016/S1473-3099(22)00420-0
2022
Book
Frontiers of COVID-19: Scientific and clinical aspects of the novel coronavirus 2019
Sasan Adibi, Paul Griffin, Melvin Sanicas, Maryam Rashidi and Francesco Lanfranchi eds. (2022). Frontiers of COVID-19: Scientific and clinical aspects of the novel coronavirus 2019. Cham, Switzerland: Springer. doi: 10.1007/978-3-031-08045-6
Funding
Past funding
Supervision
Availability
- Professor Paul Griffin is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
Contact Professor Paul Griffin directly for media enquiries about:
- COVID-19
- Infectious Diseases
- microbiology
- Vaccines
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: